Dual targeting of 3CL^pro and PL^pro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19.

ABSTRACT: With the rapid growth of the COVID-19 (coronavirus disease 2019) pandemic across the globe, therapeutic attention must be directed to fight the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, developing new antiviral drugs and vaccines is time-consuming, so one of the best solutions to tackle this virus at present is to repurpose ready-to-use drugs. This paper proposes the repurposing of the Food and Drug Administration (FDA)-approved, purchasable, and naturally occurring drugs for preventive and therapeutic use. We propose to design a dual-inhibitor for the SARS-CoV-2 cysteine proteases-3 Chemotrypsin-like protease or main protease (3CL^pro or M^pro) and Papain-like protease (PL^pro) responsible for processing the translated polyp

SUBMITTER: Rajpoot S 

PROVIDER: S-EPMC7726703 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature